Samuel Waksal Ph.D

Samuel Waksal Ph.D General Information

Biography

Dr. Samuel Waksal is the Founder & serves as Co-Chief Executive Officer at Graviton BioScience. He is a Co-Founder and serves as Chief Executive Officer at Equilibre BioPharmaceuticals. He is the Founder of Kadmon Corporation and also serves as it's Chief of Innovation, Science, and Strategy and Chairman. He is a Co-Founder and former President and Chief Executive Officer of ImClone Systems (sold to Eli Lilly & Company in 2008 for $6.5 billion). He is a distinguished figure in biotech innovation. His career is marked by founding and leading several pioneering biotech companies. He founded and led ImClone Systems, a company that redefined biotech innovation and led to a $7 billion acquisition by Eli Lilly & Company. Dr. Waksal also founded Meira GTx, a leader in gene therapy innovation. He also founded and led Kadmon Corporation, where he was pivotal in developing a selective ROCK2 inhibitor, leading to a $2 billion acquisition by Sanofi. Dr. Waksal's academic tenure is equally robust, having served in esteemed roles at Mount Sinai School of Medicine, National Cancer Institute, as a visiting fellow at Weil Cornell Medical College, as an assistant professor at Tufts University School of Medicine and a senior scientist at the Tufts Cancer Research Center. Additionally, his work at Stanford University Medical School, as a scholar at the Leukemia Society of America, as a visiting professor at the Pasteur Institute in France and the Weizmann Institute of Science in Israel highlights his profound scientific insights.